SkyAI, Inc.
NASDAQ:STSSMedical - Instruments & Supplies
+$0.00 today
- Market cap
- $55.65M
- Beta
- 2.02
- P/E (TTM)
- 1.3
- EPS (TTM)
- $0.91
Volume 0.00M
Average 0.37M
STSS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
SkyAI, Inc.NASDAQ: STSS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $137.1K rose 67.2% year over year, ahead of the -20.4% change in trailing-twelve-month research & development. Over 3 fiscal years it compounded at -50.4% a year.
Context
- Research & development amounted to 97.4% of revenue in FY2025.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +67.2% holds above the trailing-twelve-month pace of -20.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 198.76K USD
- Year-over-year change
- +442.5%
- 4-year CAGR
- -41.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 198.76K | +442.5% |
| FY2024 | 2024-12-31 | (58.03K) | -108.0% |
| FY2023 | 2023-12-31 | 729.48K | -55.3% |
| FY2022 | 2022-12-31 | 1.63M | -3.4% |
| FY2021 | 2021-12-31 | 1.69M | — |
Research & Development vs competitors
How STSS compares with its peers on the latest reported figures
- STSS's LTM Mar 2026 research & development of $319.38K is the 9th highest of the 10 companies compared; the peer median is $7.56M.
- Its year-over-year change of -20.4% is the 8th highest of 9, against a peer median of -8.6%.
- Research & development amounts to 80.5% of revenue for STSS, versus a peer median of 38.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $32.45M | -22.6% | +7.0% | — | |
| LTM Mar 2026 | $15.76M | +21.0% | +38.5% | — | |
| LTM Mar 2026 | $13.34M | -7.2% | +1.9% | 38.8% | |
| LTM Mar 2026 | $12.87M | -10.5% | -2.6% | 22573.7% | |
| LTM Mar 2026 | $7.56M | +84.3% | +13.2% | 6.1% | |
| LTM Mar 2026 | $6.11M | -11.4% | -6.7% | 5814.3% | |
| LTM Mar 2026 | $5.46M | -7.8% | +691.2% | 106.3% | |
| LTM Mar 2026 | $3.23M | -9.4% | +6.9% | 4.3% | |
| LTM Mar 2026 | $319.38K | -20.4% | -50.4% | 80.5% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding STSS) | $7.56M | -8.6% | +6.9% | 38.8% | |
Competitors are the stored peer set for STSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 204.12K |
| Cost of Revenue | 28.7K | 654.57K | 891.25K | 773.9K | 617.45K |
| Gross Profit | (28.7K) | (654.57K) | (891.25K) | (773.9K) | (413.33K) |
| Gross Margin | — | — | — | — | -202.5% |
| Research & Development | 1.69M | 1.63M | 729.48K | (58.03K) | 198.76K |
| Selling, General & Admin | 2.78M | 6.45M | 8.52M | 7.14M | 19.49M |
| Operating Expenses | 4.47M | 8.08M | 9.24M | 7.08M | 12.88M |
| Depreciation & Amortization | 28.7K | 654.57K | 891.25K | 773.9K | 132.54K |
| EBITDA | (4.47M) | (2.66M) | (8.98M) | (6.85M) | (269.74M) |
| EBITDA Margin | — | — | — | — | -132145.5% |
| Operating Income | (4.5M) | (8.74M) | (10.13M) | (7.86M) | (13.29M) |
| Operating Margin | — | — | — | — | -6512.1% |
| Interest Income | 769 | 1.32K | 138.12K | 40.3K | 0 |
| Interest Expense | 167.52K | 1.32M | 0 | 1.71M | 416.66K |
| Other Income / Expenses | (166.75K) | 4.1M | 255.01K | (1.47M) | (257.04M) |
| Income Before Tax | (4.66M) | (4.64M) | (9.87M) | (9.33M) | (270.34M) |
| Pre-Tax Margin | — | — | — | — | -132439.5% |
| Income Tax Expense | 0 | 0 | (30K) | (30K) | 0 |
| Net Income | (4.66M) | (4.64M) | (9.84M) | (9.3M) | (282.5M) |
| Net Margin | — | — | — | — | -138400.0% |
| EPS (Basic) | (3,356.30) | (3,780.28) | (4,983.99) | (2,220.05) | (11.16) |
| EPS (Diluted) | (3,356.30) | (3,780.28) | (4,983.99) | (2,220.05) | (11.16) |
| Weighted Avg Shares | 1.39K | 1.23K | 1.97K | 4.19K | 25.31M |
| Weighted Avg Shares (Diluted) | 1.39K | 1.23K | 1.97K | 4.19K | 25.31M |
SkyAI, Inc.
NASDAQ:STSS
Intrinsic Alpha fair value
Locked
Current Price
$1.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.